860780 | α-Galactosyl FP20
6-O-α-D-Galactopyranosyl-1β,2N,3-tridodecanoyl-D-glucosamine-4-phosphate, sodium salt
Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
α-Galactosyl FP20
6-O-α-D-Galactopyranosyl-1β,2N,3-tridodecanoyl-D-glucosamine-4-phosphate, sodium salt
α-Galactosyl FP-20 is a glycosylated fusion peptide (FP) adjuvant that targets human Toll-like receptor 4 (hTLR4) to activate intracellular signaling pathways. With this compound's inclusion of an α-galactose group, this structural analog of FP‑20 sodium salt has enhanced immunomodulatory specificity and receptor targeting precision.
Engineered for reliable, large-scale synthesis, α-Galactosyl FP-20 is optimal for innovative vaccine adjuvant research studies, especially those that require accurate, efficacious hTLR4 targeting and fine-tuned immune responses.
Application
α-Galactosyl FP-20 demonstrates potential in boosting both humoral and cellular immune responses, which makes it a promising adjuvant for immunological treatments that require TLR4 activation, such as those for autoimmunity and allergies, cancer, and infectious diseases.
This compound also draws interest from researchers in carbohydrate-driven receptor activation, who are reviewing its potential in glycolipid-based immunity modulation.
As shown by in vitro and in vivo studies, α-Galactosyl FP-20 differs from traditional lipid A or LPS-based TLR4 agonists due to its minimal systemic toxicity and robust cytokine induction capacity (e.g., IL-6, TNF-α, IFN-β).
Key Features
Lab-synthesized glycolipid adjuvant for activating hTLR4
Precise, safe, and scalable by design
Innate and adaptive immunity enhancing
Non-toxic profile as shown by preclinical studies
Packaging
Avanti Research™ provides α-Galactosyl FP-20 in 5 mg powder packaging for research use only. For sublicense discussions or larger quantities, please email our customer service representatives at customerservice@avantilipids.com.
With 50+ years of experience, we’re here to advance your research to the forefront of discovery.
C48H89NNaO16P
C 58.22%, H 9.06%, N 1.41%, Na 2.32%, O 25.85%, P 3.13%
CAS Registry Number is a Registered Trademark of the American Chemical Society
Powered by BiozJ. Med. Chem. 2023, 66, 4, 3010–3029Publication Date:February 2, 2023https://doi.org/10.1021/acs.jmedchem.2c01998
ACS Omega 2023, 8, 39, 36412–36417Publication Date:September 18, 2023https://doi.org/10.1021/acsomega.3c05363
J. Med. Chem. 2021, 64, 16, 12261–12272Publication Date:August 12, 2021https://doi.org/10.1021/acs.jmedchem.1c00896
- Certificate of Analysis (Lot No. 860780P-5MG-A-010 and 7278PHA010)
